Advertisement
Screener

Legend Biotech Corp (LEGN) Other Gains Losses

2.8 / 5 stars · 68/120 Roast Me

Legend Biotech Corp Other Gains Losses

Legend Biotech Corp (LEGN) reported Other Gains Losses of -$164.80 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.

Financial Statements › Income Statement › Other Income

ifrs-full:OtherGainsLosses · last filed 2026-03-10

  • Legend Biotech Corp other gains losses for the quarter ending 2025-12-31 was -$2.44M, a 102.19% decline year-over-year.
  • Legend Biotech Corp other gains losses for the quarter ending 2025-09-30 was $354.00K.
  • Legend Biotech Corp other gains losses for the quarter ending 2025-06-30 was -$108.13M, a 969.55% decline year-over-year.
  • Legend Biotech Corp other gains losses for the quarter ending 2025-03-31 was -$54.51M, a 209.72% decline year-over-year.
Period endOther Gains Losses 3 monthOther Gains Losses 3 month as first filedOther Gains Losses 6 monthOther Gains Losses 6 month as first filedOther Gains Losses 9 monthOther Gains Losses 9 month as first filedOther Gains Losses 12 monthOther Gains Losses 12 month as first filed
2025-12-31-$2.44M
derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10
-$2.08M
derived: sum of 2 quarters · filed 2026-03-10
-$110.21M
derived: sum of 3 quarters · filed 2026-03-10
-$164.80M
20-F · filed 2026-03-10
2025-09-30$354.00K
6-K · filed 2025-11-12
-$107.77M
derived: sum of 2 quarters · filed 2025-11-12
-$162.36M
6-K · filed 2025-11-12
-$50.94M
derived: sum of 4 quarters · filed 2026-03-10
2025-06-30-$108.13M
6-K · filed 2025-08-11
-$162.64M
6-K · filed 2025-08-11
-$51.30M
derived: sum of 3 quarters · filed 2026-03-10
-$112.95M
derived: sum of 4 quarters · filed 2026-03-10
2025-03-31-$54.51M
6-K · filed 2025-05-13
$56.83M
derived: sum of 2 quarters · filed 2026-03-10
-$4.82M
derived: sum of 3 quarters · filed 2026-03-10
$7.61M
derived: sum of 4 quarters · filed 2026-03-10
2024-12-31$111.34M
derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10
$49.69M
derived: sum of 2 quarters · filed 2026-03-10
$62.12M
derived: sum of 3 quarters · filed 2026-03-10
$111.80M
20-F · filed 2026-03-10
$109.38M
20-F · filed 2025-03-11
2024-09-30-$61.66M
6-K · filed 2025-11-12
-$49.22M
derived: sum of 2 quarters · filed 2025-11-12
$459.00K
6-K · filed 2025-11-12
$21.00K
6-K · filed 2024-11-12
-$35.43M
derived: sum of 4 quarters · filed 2026-03-10
2024-06-30$12.44M
6-K · filed 2025-08-11
$62.12M
6-K · filed 2025-08-11
$60.93M
6-K · filed 2024-08-09
$26.22M
derived: sum of 3 quarters · filed 2026-03-10
$36.44M
derived: sum of 4 quarters · filed 2026-03-10
2024-03-31$49.68M
6-K · filed 2025-05-13
$49.51M
6-K · filed 2024-05-13
$13.79M
derived: sum of 2 quarters · filed 2026-03-10
$24.01M
derived: sum of 3 quarters · filed 2026-03-10
$24.18M
derived: sum of 4 quarters · filed 2026-03-10
2023-12-31-$35.89M
derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10
-$25.67M
derived: sum of 2 quarters · filed 2026-03-10
-$25.50M
derived: sum of 3 quarters · filed 2026-03-10
-$24.80M
20-F · filed 2026-03-10
$663.00K
20-F · filed 2024-03-19
2023-09-30$10.22M
derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12
$10.39M
derived: sum of 2 quarters · filed 2024-11-12
$11.09M
6-K · filed 2024-11-12
$12.20M
derived: sum of 4 quarters · filed 2025-03-11
2023-06-30$168.00K
derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09
$873.00K
6-K · filed 2024-08-09
$1.98M
derived: sum of 3 quarters · filed 2025-03-11
$2.07M
derived: sum of 4 quarters · filed 2025-03-11
2023-03-31$705.00K
6-K · filed 2024-05-13
$1.81M
derived: sum of 2 quarters · filed 2025-03-11
$1.90M
derived: sum of 3 quarters · filed 2025-03-11
2022-12-31$1.10M
derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11
$1.20M
derived: sum of 2 quarters · filed 2025-03-11
$1.34M
20-F · filed 2025-03-11
2022-09-30$94.00K
derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20
$243.00K
6-K · filed 2023-11-20
2022-06-30$149.00K
6-K · filed 2023-08-15
2021-12-31$317.00K
20-F · filed 2024-03-19
2020-12-31$113.00K
20-F · filed 2023-03-30
2019-12-31$1.06M
20-F/A · filed 2023-02-17
$724.00K
20-F · filed 2022-03-31